BlackRock Fund Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
$9.83M Buy
362,192
+95,640
+36% +$2.44M ﹤0.01% 2584
2016
Q3
$6.83M Buy
266,552
+31,856
+14% +$676K ﹤0.01% 2680
2016
Q2
$4.33M Buy
234,696
+87,739
+60% +$1.74M ﹤0.01% 2878
2016
Q1
$2.79M Sell
146,957
-8,229
-5% -$157K ﹤0.01% 2983
2015
Q4
$4.18M Buy
+155,186
New +$3.02M ﹤0.01% 2924

Other funds holding ACRS

BlackRock Fund Advisors's ACRS Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Aclaris Therapeutics (ACRS) stake by 36% in Q4 2016, buying an estimated $2.44M and bringing the position to 362,192 shares worth $9.83M. The position accounts for ﹤0.01% of the portfolio, ranked #2584.

BlackRock Fund Advisors first reported a position in ACRS in Q4 2015 and has held it in 5 quarters since. 100 funds tracked by Wall St. Rank hold ACRS as of Q4 2016.

  • BlackRock Fund Advisors held 362,192 shares of Aclaris Therapeutics worth $9.83M as of Q4 2016.
  • BlackRock Fund Advisors bought 95,640 Aclaris Therapeutics shares in Q4 2016, an estimated $2.44M.
  • Aclaris Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #2584 holding.
  • BlackRock Fund Advisors first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 5 quarters since.
  • 100 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.